AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...
Verschillende goede voorbeelden met aantoonbare impact vormen de basis voor de afspraken over de doorbraakmiddelen.
Met een nieuwe app screenen COPD patiënten zich thuis op atriumfibrilleren, wat vroege opsporing van atriumfibrilleren bij ...
COPD treft wereldwijd bijna 400 miljoen mensen en is de derde doodsoorzaak ter wereld. Meer dan 50% van de patiënten die de inhalatiestandaard gebruiken, ervaart exacerbaties, die het risico op ...
AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded mixed data for Roche and ...
In support of World COPD Day on November 19, the Global Initiative for Chronic Obstructive Lung Disease (GOLD), is drawing attention to the importance of correctly diagnosing COPD earlier - with the ...
Chronic obstructive pulmonary disease, or COPD, is often thought of as a condition that only affects longtime smokers. In reality, the disease reaches far beyond that group. Women are ...
COPD Infection Management and Mitigation Strategies: Focusing on Diagnostics and Targeted Treatments
As the “Swiss Army knife of bacteria,” methicillin-resistant Staphylococcus aureus is quite the problematic organism, said John Osiecki, PhD. Among the diverse group of gram-positive bacteria ...
Chronic obstructive pulmonary disease, or COPD, is the fourth leading cause of death worldwide, responsible for 3.5 million deaths in 2021, according to the World Health Organization. It’s a common ...
COPD affects at least 4.5% of those 18-49 years old, according to an analysis of U.S. cohorts. The early COPD group was more likely to be hospitalized or die from chronic respiratory disease, to ...
Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken a hit after the anti-ST2 monoclonal antibody failed to reduce flare-ups in ...
Scientists have discovered that people with COPD have lung cells that contain over three times as much soot-like carbon as those of smokers without the disease. These overloaded cells are larger and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results